Jain Global LLC Sells 22,417 Shares of Waters Corporation $WAT

Jain Global LLC reduced its stake in shares of Waters Corporation (NYSE:WAT) by 26.2% in the third quarter, HoldingsChannel reports. The firm owned 63,281 shares of the medical instruments supplier’s stock after selling 22,417 shares during the period. Jain Global LLC’s holdings in Waters were worth $18,972,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its stake in Waters by 112.9% in the fourth quarter. Brighton Jones LLC now owns 1,269 shares of the medical instruments supplier’s stock valued at $471,000 after purchasing an additional 673 shares during the last quarter. Integrated Wealth Concepts LLC lifted its position in shares of Waters by 2.9% during the first quarter. Integrated Wealth Concepts LLC now owns 1,048 shares of the medical instruments supplier’s stock valued at $386,000 after buying an additional 30 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Waters by 3.6% during the first quarter. Goldman Sachs Group Inc. now owns 200,051 shares of the medical instruments supplier’s stock valued at $73,733,000 after buying an additional 6,976 shares during the last quarter. Empowered Funds LLC boosted its holdings in shares of Waters by 16.6% in the 1st quarter. Empowered Funds LLC now owns 1,126 shares of the medical instruments supplier’s stock valued at $415,000 after buying an additional 160 shares in the last quarter. Finally, Sivia Capital Partners LLC bought a new stake in shares of Waters in the 2nd quarter valued at about $232,000. Institutional investors own 94.01% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on WAT shares. Citigroup began coverage on shares of Waters in a research report on Tuesday, February 10th. They issued a “buy” rating and a $425.00 price objective on the stock. Robert W. Baird set a $363.00 target price on shares of Waters in a research note on Tuesday, February 10th. Guggenheim reaffirmed a “buy” rating and issued a $440.00 price target on shares of Waters in a report on Tuesday, February 10th. Wall Street Zen downgraded Waters from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. Finally, Bank of America decreased their price objective on Waters from $410.00 to $350.00 and set a “neutral” rating for the company in a report on Tuesday, February 10th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $393.84.

Waters Stock Performance

WAT opened at $286.42 on Monday. The company has a market cap of $28.10 billion, a P/E ratio of 26.59, a price-to-earnings-growth ratio of 1.97 and a beta of 1.20. The company has a quick ratio of 1.27, a current ratio of 1.73 and a debt-to-equity ratio of 0.37. The firm’s 50-day moving average price is $352.67 and its 200-day moving average price is $351.58. Waters Corporation has a 52-week low of $275.05 and a 52-week high of $414.15.

Waters (NYSE:WAT) last released its earnings results on Monday, February 9th. The medical instruments supplier reported $4.53 EPS for the quarter, topping analysts’ consensus estimates of $4.50 by $0.03. The company had revenue of $932.36 million during the quarter, compared to analysts’ expectations of $928.17 million. Waters had a net margin of 20.30% and a return on equity of 34.79%. Waters’s revenue for the quarter was up 6.9% on a year-over-year basis. During the same period last year, the business earned $4.10 EPS. Waters has set its FY 2026 guidance at 14.300-14.500 EPS and its Q1 2026 guidance at 2.250-2.350 EPS. As a group, equities analysts anticipate that Waters Corporation will post 12.86 EPS for the current fiscal year.

About Waters

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.